Danaher, jennifer doudna, and innovative genomics institute launch danaher-igi beacon for crispr cures with aim to address hundreds of diseases using gene-editing platform solution

New collaborative research center based at university of california, berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding nobel laureate doudna and team to partner with danaher to oversee center's translational and clinical research washington , jan. 9, 2024 /prnewswire/ -- danaher corporation (nyse: dhr) and the innovative genomics institute (igi) today launched a collaborative center to develop gene-editing therapies for rare and other diseases, with a goal of creating a new model for future development of a wide range of genomic medicines. the center, known as the danaher-igi beacon for crispr cures, aims to use crispr-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.
DHR Ratings Summary
DHR Quant Ranking